Qureight, a Cambridge, UK-based biotech company providing a drug development platform, raised $8.5M in Series A funding.
The round was led by Hargreave Hale AIM VCT with participation from XTX Ventures, Guinness Ventures, Playfair Capital, Meltwind, Ascension Life Fund and Cambridge Angels.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO Dr Muhunthan Thillai, Qureight accelerates clinical trial development at key decision points through data curation and AI-powered decision making. It leverages a platform that collects data and analyse it via AI models, which can help researchers make more informed decisions. The clinical trials market is globally projected to reach over $92bn by 2030.
The company partners with pharma companies such as AstraZeneca and Vicore Pharma and signed R&D contracts with five NHS England trusts.
FinSMEs
22/04/2024